Home Cart Sign in  
Chemical Structure| 14534-61-3 Chemical Structure| 14534-61-3

Structure of Isochlorogenic acid B
CAS No.: 14534-61-3

Chemical Structure| 14534-61-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

3,4-Dicaffeoylquinic Acid is a polyphenol with diverse biological activities, it inhibits acetylcholinesterase (ACE) and α-glucosidase in a concentration-dependent manner, shows cytotoxic to NCI-H23 lung adenocarcinoma cells, as well as increases tumor necrosis factor-related apoptosis inducing ligand (TRAIL) mRNA, reduces influenza H1N1 hemagglutinin (HA) mRNA and increases survival in a mouse model of influenza A infection.

Synonyms: 3,4-Dicaffeoylquinic acid; 3,4-Di-O-caffeoylquinic acid; 3,4-DCQA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Isochlorogenic acid B

CAS No. :14534-61-3
Formula : C25H24O12
M.W : 516.45
SMILES Code : O=C([C@@]1(O)C[C@@H](OC(/C=C/C2=CC=C(O)C(O)=C2)=O)[C@H](OC(/C=C/C3=CC=C(O)C(O)=C3)=O)[C@H](O)C1)O
Synonyms :
3,4-Dicaffeoylquinic acid; 3,4-Di-O-caffeoylquinic acid; 3,4-DCQA
MDL No. :MFCD08272439

Safety of Isochlorogenic acid B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HaCaT cells 10 and 100 μmol/L 12 hours Rescues TRPV3 agonist carvacrol-induced cell death Acta Pharm Sin B. 2022 Feb;12(2):723-734
HEK293 cells 0.9 ± 0.3 μmol/L (IC50) Selectively inhibits TRPV3 currents with IC50 of 0.9 ± 0.3 μmol/L, significantly reduces channel open probability Acta Pharm Sin B. 2022 Feb;12(2):723-734
human rhabdomyosarcoma (RD) cells 50 μM 1 hour To evaluate the inhibitory effect of 3,4-DCQA on EV-A71-induced cytopathic effects, results showed that 3,4-DCQA effectively protected cells from EV-A71 infection. J Virol. 2022 Apr 13;96(7):e0054221

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
ICR mice High blood glucose mouse model (T2D) Intragastric administration 30 mg/kg Once daily for 28 days To evaluate the hypoglycemic activity of isochlorogenic acid B, the results showed that isochlorogenic acid B significantly reduced blood glucose levels in high blood glucose mice. Molecules. 2024 Oct 13;29(20):4848
C57BL/6J mice Dermatitis and chronic pruritus model Topical application 1.0 mmol/L (50 μL) 6 consecutive days Significantly attenuates ear swelling and chronic scratching behavior Acta Pharm Sin B. 2022 Feb;12(2):723-734

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.94mL

0.39mL

0.19mL

9.68mL

1.94mL

0.97mL

19.36mL

3.87mL

1.94mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories